# Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

> **NCT06940518** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Ivonescimab
- Clear Cell Renal Carcinoma

## Interventions

- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT06940518
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2028-01-19
- **Final completion:** 2030-01-19
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940518, "Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06940518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*